KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $4.6 million.

  • Aurinia Pharmaceuticals' Current Deferred Revenue rose 692.38% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 692.38%. This contributed to the annual value of $11.0 million for FY2024, which is 12858.92% up from last year.
  • Aurinia Pharmaceuticals' Current Deferred Revenue amounted to $4.6 million in Q3 2025, which was up 692.38% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue ranged from a high of $11.0 million in Q4 2024 and a low of $190000.0 during Q4 2021
  • In the last 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue had a median value of $4.6 million in 2025 and averaged $4.5 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Current Deferred Revenue skyrocketed by 155684.21% in 2022 and then plummeted by 767.91% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $190000.0 in 2021, then soared by 1556.84% to $3.1 million in 2022, then soared by 52.89% to $4.8 million in 2023, then skyrocketed by 128.59% to $11.0 million in 2024, then crashed by 58.17% to $4.6 million in 2025.
  • Its Current Deferred Revenue stands at $4.6 million for Q3 2025, versus $5.5 million for Q2 2025 and $4.6 million for Q1 2025.